扩展HPV基因分型与双染在初筛HPV阳性病例分流中的应用:细胞病理实验室实践指南
本文综述了美国宫颈癌预防中初筛HPV阳性病例的分流策略,重点介绍扩展HPV基因分型和p16/Ki-67双染免疫细胞化学两种已获FDA批准并纳入指南的分流检测,以及2024年5月批准的阴道自采样。文章讨论了实施前需考虑的问题,并为细胞病理实验室将自采样标本和扩展基因分型/双染检测纳入工作流程提供实践指导。
要点
- 初筛HPV阳性需分流,理想分流试验应平衡癌前病变敏感性与阴道镜数量。
- 扩展HPV基因分型和p16/Ki-67双染已获FDA批准并纳入筛查管理指南。
- 自采样标本仅能用初筛HPV平台检测,管理指南已获ASCCP认可。
核心结论
- 扩展HPV基因分型和p16/Ki-67双染可作为初筛HPV阳性病例的分流方法,其实施需经过适当的验证和培训。
- 阴道自采样可增加筛查可及性,但标本仅能用初筛HPV平台检测。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 自2020年起美国癌症协会推荐初筛HPV作为首选筛查方法,其阴性预测值高。
- 初筛HPV阳性者需分流,理想分流试验应最大化特异性并安抚阴性患者,但无检测能完全排除疾病。
- 宫颈细胞学分流目前为多数筛查策略推荐,扩展基因分型和双染为额外分流选择。
- FDA于2024年5月批准阴道自采样,样本仅能用初筛HPV平台检测。
关键数值与推荐
- 扩展HPV基因分型和p16/Ki-67双染免疫细胞化学已获FDA批准并纳入宫颈癌筛查和管理指南。
- 双染免疫细胞化学实施需适当的细胞技师/细胞病理医师培训。
- 自采样标本管理指南已获ASCCP持续指南流程认可。
临床怎么用
- 细胞病理实验室在引入扩展基因分型或双染前应进行适当的验证/确认和实施步骤。
- 双染检测需对细胞技师和细胞病理医师进行培训。
- 自采样标本应使用初筛HPV平台检测,并遵循ASCCP认可的管理指南。
局限性
- 无筛查或分流检测能完全排除初筛阳性患者的疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of many factors, the landscape of cervical cancer prevention is again at a pivot point within the United States. Primary human papillomavirus (HPV) screening has been recommended as the preferred testing method by the American Cancer Society since 2020. Although primary HPV testing provides high negative predictive value in screening, women who screen positive for HPV need triage using methods that have an optimal balance between sensitivity for precancer and the number of colposcopies required for detection. The triage test ideally should maximize specificity while also reassuring patients who test negative, although it should be acknowledged that no screening or triage test can entirely exclude disease in a screen-positive patient. While cervical cytology (the Papanicolaou test) triage of primary HPV screen-positive patients is currently recommended by most screening strategies, additional triage tests, specifically extended HPV genotyping and combined p16/Ki-67 dual-stain immunocytochemistry, are now approved by the US Food and Drug Administration and incorporated into cervical cancer screening and management guidelines. Incorporating these triage methods into practice should be achieved by using appropriate validation/verification and implementation steps and, in the case of dual-stain immunocytochemistry, appropriate cytologist/cytopathologist training. The US Food and Drug Administration approval of vaginal self-collection in May 2024 is another significant advance for increasing access to screening. These samples can only be tested using primary HPV screening platforms, and guidance for management has been endorsed by the ASCCP's enduring guidelines process. This review discusses issues that warrant consideration before implementation and provides practical guidance for the incorporation of self-collected specimens and extended genotyping/dual-stain tests into the workflow of the cytopathology laboratory.
引用
- Goulart RA, Nayar R, Lorey T, et al. Extended HPV genotyping and dual stain for the triage of primary HPV screen-positive cases: Practical guidance for the cytopathology laboratory. Cancer Cytopathol. 2025. PMID: 40055959. doi:10.1002/cncy.70006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。